Study of Sotagliflozin and Ketogenic Diet to Improve Heart Glucose Suppression in Cardiac Sarcoidosis Evaluation Using FDG PETCT

What this Trial Is About

This research aims to evaluate whether adding a sodium-glucose cotransporter-12 inhibitor SGLT12i, specifically sotagliflozin, to a ketogenic diet can improve myocardial glucose suppression during FDG PETCT scans. The study focuses on healthy adult volunteers and investigates if 7 days of sotagliflozin combined with 1 or 3 days of a ketogenic diet enhances the hearts glucose suppression, which is important for better imaging quality in cardiac sarcoidosis evaluation. The study also explores the relationship between sotagliflozin, metabolite levels, and heart glucose use. Participants will take sotagliflozin 400 mg once daily for about 7 days before undergoing the FDG PETCT scan. They will follow a ketogenic diet for either 1 day or 3 days leading up to the scan, with overnight fasting before the imaging. The PETCT scan uses a special tracer to measure glucose activity in the heart. The study includes two groups of 20 volunteers each, differing by the length of the ketogenic diet before the scan. Participants will track their medication and diet intake in diaries. During the study, participants will have blood tests, vital sign checks, and health history reviews at screening and on the scan day. Blood samples will be analyzed for various metabolic markers to understand how they relate to heart glucose suppression. The diet diary will be reviewed to assess adherence to the ketogenic diet. The main outcome measures include the rate of complete heart glucose suppression and myocardial glucose use. The total participation time covers screening, 7 to 10 days of medication and diet, and the scan visit.

Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression